Lataa...
Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer
KRAS mutations are associated with tumor resistance to EGFR TKIs (erlotinib, gefitinib) and to monoclonal antibody against EGFR (cetuximab). Targeted treatment of mutated RAS patients is still considered as a challenge. Inhibitors of c-Met (onartuzumab or tiwantinib) and MEK (selumetinib—a dual inhi...
Tallennettuna:
| Julkaisussa: | Clin Exp Med |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer International Publishing
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4844634/ https://ncbi.nlm.nih.gov/pubmed/25902737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10238-015-0349-2 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|